Piergiorgio Malagoli
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications
Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).
Journal: Dermatology and therapy
Published: July 14, 2026
Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.
Journal: The British journal of dermatology
Published: May 16, 2026
Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).
Journal: Journal of clinical medicine
Published: April 17, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.
Journal: Dermatology and therapy
Published: April 10, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.
Journal: Dermatology and therapy
Published: March 11, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.
Journal: Dermatology and therapy
Published: March 04, 2026
Toward the definition of moderate psoriasis: an expert opinion.
Journal: The Journal of dermatological treatment
Published: February 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort.
Journal: The Journal of dermatological treatment
Published: January 23, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis).
Journal: Dermatology and therapy
Published: December 26, 2025
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis).
Journal: Dermatology and therapy
Published: December 01, 2025
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).
Journal: Acta dermato-venereologica
Published: November 16, 2025
Last Updated: 09/26/2026